
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CLR 125
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Cellectar
Deal Size : Undisclosed
Deal Type : Agreement
Cellectar, Evestia Partner for Auger-Emitting Radiopharmaceutical Trial in TNBC
Details : Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC).
Product Name : CLR 125
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
September 24, 2025
Lead Product(s) : CLR 125
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Cellectar
Deal Size : Undisclosed
Deal Type : Agreement
